Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Debt to Equity (2017 - 2023)

Sutro Biopharma's Debt to Equity history spans 7 years, with the latest figure at $0.03 for Q4 2023.

  • For Q4 2023, Debt to Equity fell 63.8% year-over-year to $0.03; the TTM value through Dec 2023 reached $0.03, down 63.8%, while the annual FY2023 figure was $0.03, 63.8% down from the prior year.
  • Debt to Equity for Q4 2023 was $0.03 at Sutro Biopharma, down from $0.06 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.29 in Q1 2020 and bottomed at $0.03 in Q4 2023.
  • The 5-year median for Debt to Equity is $0.09 (2021), against an average of $0.1.
  • The largest annual shift saw Debt to Equity soared 199.42% in 2019 before it tumbled 72.71% in 2021.
  • A 5-year view of Debt to Equity shows it stood at $0.1 in 2019, then decreased by 26.81% to $0.07 in 2020, then skyrocketed by 34.51% to $0.1 in 2021, then fell by 24.61% to $0.07 in 2022, then tumbled by 63.8% to $0.03 in 2023.
  • Per Business Quant, the three most recent readings for STRO's Debt to Equity are $0.03 (Q4 2023), $0.06 (Q3 2023), and $0.07 (Q2 2023).